RaNA is dedicated to advancing the treatment paradigm by spearheading the discovery of revolutionary RNA-targeted medicines that selectively upregulate gene expression within cells in the body. Our approach has broad therapeutic potential, opening up a vast number of hard-to-treat disease targets with significant need
Transcription is the first step of gene expression when DNA is copied into messenger RNA (mRNA). During this process, RaNA’s oligonucleotides, are designed to block long non-coding RNA (lncRNA) from recruiting complexes known as chromatin modifiers, which can suppress the expression of certain genes.
What’s so important about IncRNA?
By blocking the interaction between lncRNA and chromatin modifiers, transcription is activated, resulting in gene upregulation or expression. The result? The production of proteins is increased, in turn treating or preventing disease.
During post-transcription – after DNA is copied into mRNA but before translation – mRNA decay occurs naturally within our cells. Half-lives of mRNA limit the amount of therapeutic protein available in our bodies.
In patients with certain diseases, this presents an opportunity. RaNA’s oligonucleotides are designed to stabilize the structure of mRNA, increasing its half-life, thus increasing protein levels, which are important in treating and preventing disease.